CCS Integrated Cases

CCS case: chest pain in the ED with troponin elevation

Clinical Overview and When to Suspect Acute Coronary Syndrome

— ~8 million ED visits/year in the US for chest pain; ~15–25% are ACS.

— Prevalence rises sharply with age >55 (men) or >65 (women), known CAD, diabetes, CKD, tobacco, and family history of premature CAD.

— Substernal pressure/heaviness lasting >10 min, exertional or rest, radiating to jaw/left arm, with diaphoresis, dyspnea, or nausea.

— Anginal equivalents in diabetics, women, elderly: dyspnea, fatigue, epigastric pain, syncope.

— New heart failure, new arrhythmia, or hemodynamic instability with chest discomfort.

— High-sensitivity troponin (hs-cTn) >99th percentile URL with rise/fall pattern = acute myocardial injury.

— Type 1 MI: plaque rupture/thrombosis.

— Type 2 MI: supply-demand mismatch (sepsis, tachyarrhythmia, anemia, hypotension, hypertensive crisis).

— Non-ischemic injury: myocarditis, Takotsubo, PE, CKD, heart failure, contusion.

Definition: Acute coronary syndrome (ACS) encompasses unstable angina (UA), non–ST-elevation MI (NSTEMI), and ST-elevation MI (STEMI). On the CCS case interface, "chest pain + troponin elevation" almost always signals NSTEMI or type 2 MI until proven otherwise.

Epidemiology and pretest probability:

When to suspect ACS in the ED:

Troponin elevation framing:

CCS pearl: On the case clock, the moment you see "chest pain" as chief complaint, your first three orders should already be queued mentally — ECG within 10 minutes, IV access, continuous cardiac monitoring. The CCS grader rewards rapid recognition more than exhaustive history.

Board pearl: A single normal troponin does not exclude ACS if symptoms began <3 hours ago — repeat hs-cTn at 1–3 h per the 0/1-h or 0/3-h algorithm. Serial troponins with a delta >20% (or absolute change above assay cutoff) define acute injury and shift you from "rule-out" to "rule-in" pathways.

Presentation Patterns and Key History

— Substernal pressure, tightness, or squeezing.

— Provoked by exertion or emotion, relieved by rest or nitroglycerin within 5 minutes.

— Radiation to left arm, both arms, jaw, or interscapular area.

— Associated diaphoresis, dyspnea, nausea, lightheadedness.

— Women: fatigue, jaw or back pain, nausea, dyspnea.

— Elderly (>75): confusion, syncope, isolated dyspnea, falls.

— Diabetics: silent ischemia from autonomic neuropathy; presenting as new CHF or hyperglycemia.

— Post-op or critically ill: hypotension, new arrhythmia, troponin bump without pain (type 2 MI).

— Onset, duration, character, radiation, provocation, palliation.

— Prior MI/PCI/CABG, stents (drug-eluting vs bare-metal, date), prior stress test results.

— Risk factors: HTN, DM, dyslipidemia, smoking, family history of premature CAD (<55 M / <65 F), cocaine/methamphetamine use.

— Bleeding history, recent surgery, stroke, anticoagulant use — affects antiplatelet/anticoagulant choice.

— Medications: aspirin, P2Y12, statin, beta-blocker, PDE-5 inhibitors (contraindicate nitrates within 24–48 h).

— Tearing pain to back, BP differential → aortic dissection.

— Pleuritic pain, hemoptysis, unilateral leg swelling → PE.

— Fever, positional pain relieved leaning forward → pericarditis/myocarditis.

Classic anginal pattern (high likelihood ACS):

Atypical/anginal-equivalent presentations (do not dismiss):

Targeted history (5–10 case-clock minutes):

Red flags suggesting alternative dangerous diagnosis:

Key distinction: Pain reproducible by palpation does not rule out ACS — up to 7% of confirmed MIs have reproducible chest wall tenderness. Pleuritic, positional, or sharp pain reduces but does not eliminate ACS probability.

CCS pearl: Document cocaine/stimulant use early — it changes pharmacotherapy (avoid pure beta-blockers acutely; use benzodiazepines, nitrates, CCBs first) and alters the case branch point.

Physical Exam Findings and Hemodynamic Assessment

— Diaphoresis, pallor, anxious "Levine sign" (clenched fist over sternum) — classic but nonspecific.

— Cool extremities, mottling, altered mentation → cardiogenic shock until proven otherwise.

— HR: tachycardia from pain/SNS activation; bradycardia in inferior MI (vagal, RCA territory).

— BP: hypertension common; hypotension is ominous — think RV infarct, cardiogenic shock, mechanical complication, or tamponade.

— RR/SpO2: hypoxia suggests pulmonary edema, PE, or pneumothorax. Do not give supplemental O2 routinely if SpO2 ≥90% — may increase infarct size.

— Bilateral arm BPs if dissection suspected.

— S4 gallop: reduced LV compliance from ischemia.

— S3 gallop: LV dysfunction/heart failure → worse prognosis.

— New systolic murmur: papillary muscle dysfunction/rupture (mitral regurgitation) or ventricular septal rupture — mechanical complications, typically days 3–7.

— Pericardial friction rub: post-MI pericarditis or alternative diagnosis.

— Bibasilar crackles → pulmonary edema (Killip class II–III).

— Clear lungs with hypotension and elevated JVP → RV infarct or tamponade.

— I: no failure (mortality ~6%).

— II: rales/S3 (~17%).

— III: frank pulmonary edema (~38%).

— IV: cardiogenic shock (~67–80%).

— Asymmetric pulses or BP → dissection.

— Unilateral leg edema → DVT/PE consideration.

— Femoral/radial pulses palpated pre-cath access.

General appearance:

Vital signs (CCS: review every reassessment):

Cardiac exam:

Pulmonary exam:

Killip classification (bedside prognosis in MI):

Extremities/vascular:

CCS pearl: On every CCS reassessment after intervention (nitro, fluids, morphine), re-check BP, HR, lungs, mental status. The grader credits serial focused exams over single comprehensive ones.

Board pearl: Hypotension + clear lungs + elevated JVP in inferior STEMI = RV infarct. Treat with IV fluid bolus; avoid nitrates and diuretics.

Diagnostic Workup — Initial Labs, ECG, and Biomarkers

— 12-lead ECG within 10 minutes of ED arrival — repeat q15–30 min if initial nondiagnostic and symptoms persist.

— IV access ×2, continuous cardiac monitoring, pulse oximetry, BP cuff.

— hs-Troponin at 0 and 1 h (or 0 and 3 h depending on assay).

— CBC, BMP (K, Mg, Cr, glucose), magnesium, PT/INR, aPTT, lipid panel, BNP.

— CXR portable — assess pulmonary edema, mediastinal widening, pneumothorax.

— Type and screen if invasive strategy anticipated.

— STEMI criteria: ≥1 mm ST elevation in ≥2 contiguous limb leads, or ≥2 mm (men)/≥1.5 mm (women) in V2–V3.

— New LBBB with ischemic symptoms — apply Sgarbossa criteria (concordant ST elevation ≥1 mm, concordant ST depression V1–V3, or discordant ST elevation ≥5 mm).

— Posterior MI: ST depression V1–V3 with tall R waves; confirm with V7–V9 leads.

— Inferior MI (II, III, aVF): always obtain right-sided leads (V4R) to detect RV infarct.

— NSTEMI/UA: ST depression ≥0.5 mm, T-wave inversion ≥1 mm, or transient ST elevation.

— Wellens syndrome: deep symmetric T-wave inversions or biphasic T in V2–V3 → critical proximal LAD lesion.

— Rule-out: very low baseline AND no delta at 1 h.

— Rule-in: baseline above high cutoff OR significant 1-h delta.

— Observe zone: repeat at 3 h, consider alternative diagnoses.

Order set on arrival (CCS clock 0–10 minutes):

ECG interpretation priorities:

High-sensitivity troponin algorithm (ESC 0/1-h):

Board pearl: De Winter T waves (upsloping ST depression with tall symmetric T waves in precordial leads) = proximal LAD occlusion equivalent — activate cath lab even without ST elevation.

CCS pearl: Order the repeat ECG explicitly at "15 minutes" or "with any change in pain" — the grader tracks reassessment density.

Diagnostic Workup — Advanced and Confirmatory Studies

— Obtain in ED or within 24 h of admission for NSTEMI; immediately if hemodynamic instability, new murmur, or suspected mechanical complication.

— Assess regional wall motion abnormalities (RWMA), LVEF, valvular function, pericardial effusion, RV size/function.

— Normal wall motion during active pain has high NPV for ischemia.

— Best for low-to-intermediate risk patients with normal/nondiagnostic ECG and negative initial troponin.

— High NPV; excludes obstructive CAD and discharges patients safely.

— Avoid if known CAD, renal insufficiency (contrast), or high pretest probability (go straight to invasive angiography).

— For low-risk chest pain after rule-out (two negative troponins, normal ECG) without prior CAD.

— Exercise treadmill ECG if baseline ECG interpretable and patient can exercise.

— Pharmacologic (regadenoson, dobutamine) with imaging if unable to exercise or uninterpretable ECG (LBBB, paced, LVH with strain, digoxin).

— Stress echo or nuclear MPI if imaging needed.

— STEMI: emergent (door-to-balloon <90 min).

— High-risk NSTEMI (GRACE >140, dynamic ECG changes, hemodynamic/electrical instability, refractory angina): within 2 h.

— Intermediate-risk NSTEMI: within 24 h.

— Low-risk NSTEMI: within 72 h or selective strategy after noninvasive testing.

— D-dimer + CTPA if PE possible.

— CT aortogram if dissection suspected (widened mediastinum, BP differential, tearing pain).

— Lipase if epigastric pain prominent.

Echocardiography (TTE):

Coronary CT angiography (CCTA):

Stress testing:

Invasive coronary angiography:

Adjunctive labs/imaging when differential broad:

Key distinction: CCTA evaluates anatomy (is there a stenosis?); stress testing evaluates physiology (is it causing ischemia?). Choose based on the question you need answered.

CCS pearl: Order TTE on Day 1 for every confirmed MI — LVEF drives ICD discussion, ACEi/ARB indication, and anticoagulation for LV thrombus.

Risk Stratification and First-Line Management Logic

— STEMI → emergent reperfusion (PCI <90 min door-to-balloon, or fibrinolysis <30 min door-to-needle if PCI unavailable within 120 min).

— NSTE-ACS → risk-stratify, then decide invasive vs ischemia-guided.

— Age ≥65, ≥3 CAD risk factors, known CAD (stenosis ≥50%), ASA use in past 7 days, ≥2 anginal episodes in 24 h, ST deviation ≥0.5 mm, positive biomarkers.

— Score 0–2 low, 3–4 intermediate, 5–7 high risk.

— >140 = high risk → early invasive (<24 h).

— 109–140 = intermediate.

— <109 = low.

— History, ECG, Age, Risk factors, Troponin (0–10).

— 0–3: low risk, discharge with outpatient follow-up.

— 4–6: admit/observe, serial troponins, stress or CCTA.

— ≥7: high risk, early invasive strategy.

— Aspirin 325 mg chewed (unless true allergy or active bleeding).

— Sublingual nitroglycerin 0.4 mg q5 min ×3 for ongoing pain (hold if SBP <90, RV infarct, PDE-5 inhibitor use).

— Atorvastatin 80 mg PO early.

— Oxygen only if SpO2 <90%.

— Pain control: morphine only if refractory to nitrates — may blunt P2Y12 absorption and worsen outcomes.

— STEMI → cath lab.

— High-risk NSTEMI → CCU/telemetry, cath within 2–24 h.

— Low-risk → observation unit, serial troponins, stress or CCTA, discharge if negative.

Initial branch point — STEMI vs NSTE-ACS:

TIMI risk score (NSTEMI/UA, 0–7 points, 1 each):

GRACE score (more granular, incorporates age, HR, SBP, Cr, Killip class, cardiac arrest, ST deviation, troponin):

HEART score (ED triage):

Immediate universal orders (CCS clock 0–30 min) for suspected ACS:

Disposition logic:

Step 3 management: Do not give prasugrel before angiography in NSTEMI (TRILOGY/ACCOAST) — defer P2Y12 loading until anatomy known if invasive strategy planned.

Pharmacotherapy — First-Line Regimen

— Aspirin 325 mg loading, then 81 mg daily indefinitely.

— P2Y12 inhibitor (dual antiplatelet therapy, DAPT) — choose one:

— Ticagrelor 180 mg load → 90 mg BID; preferred over clopidogrel in most ACS (PLATO).

— Prasugrel 60 mg load → 10 mg daily; only after anatomy known, contraindicated with prior stroke/TIA, age ≥75, weight <60 kg (use 5 mg).

— Clopidogrel 600 mg load → 75 mg daily; if fibrinolysis used, on anticoagulation, or ticagrelor/prasugrel contraindicated.

— GP IIb/IIIa inhibitors (eptifibatide, tirofiban): reserved for high thrombus burden during PCI.

— Unfractionated heparin 60 U/kg bolus (max 4000) → 12 U/kg/h infusion, titrate aPTT 1.5–2× control. Preferred if going to cath.

— Enoxaparin 1 mg/kg SC q12h (1 mg/kg daily if CrCl <30); good for medical management.

— Bivalirudin: alternative during PCI, especially with HIT history.

— Fondaparinux 2.5 mg SC daily: medical management; avoid as sole agent during PCI (catheter thrombosis).

— Beta-blocker within 24 h (metoprolol tartrate 25 mg PO BID, titrate) — avoid IV BB acutely if heart failure, hypotension, bradycardia, or risk of cardiogenic shock (COMMIT trial).

— Nitroglycerin IV for refractory chest pain, HTN, or pulmonary edema; avoid in RV infarct, SBP <90, PDE-5 use within 24–48 h.

— High-intensity statin: atorvastatin 80 mg or rosuvastatin 40 mg, regardless of LDL.

Antiplatelets:

Anticoagulation (one agent during ACS):

Anti-ischemic therapy:

ACEi/ARB: Start within 24 h if LVEF <40%, HTN, DM, or anterior MI. Lisinopril 2.5–5 mg daily, titrate.

Aldosterone antagonist (eplerenone): Add if LVEF ≤40% with symptomatic HF or DM, on ACEi/BB, K <5.0, CrCl >30.

Board pearl: Memorize the contraindications to prasugrel — prior CVA/TIA = absolute contraindication. This is a recurring distractor.

CCS pearl: Order DVT prophylaxis (enoxaparin 40 mg SC daily or heparin 5000 U SC q8h) on admission — but only if not already on therapeutic anticoagulation.

Procedures — Reperfusion and Revascularization

— STEMI: door-to-balloon ≤90 min at PCI-capable center, ≤120 min if transferred.

— Radial access preferred (lower bleeding, MATRIX trial).

— Drug-eluting stent (DES) standard; bare-metal stent only if DAPT compliance concern or imminent surgery.

— Complete revascularization of significant non-culprit lesions during index hospitalization (COMPLETE trial) for STEMI multivessel disease.

— Tenecteplase, alteplase, or reteplase within 30 min of arrival.

— Window: symptom onset <12 h (some benefit 12–24 h if ongoing ischemia).

— Absolute contraindications: prior ICH, ischemic stroke <3 months (except <4.5 h current), active bleeding, suspected aortic dissection, intracranial neoplasm/AVM, recent significant head/facial trauma <3 months.

— Transfer to PCI center afterward (pharmaco-invasive strategy) for angiography within 3–24 h.

— Left main disease ≥50%.

— Three-vessel disease, especially with DM (FREEDOM) or LV dysfunction.

— Failed PCI or complex anatomy (high SYNTAX score).

— Mechanical complications (VSD, papillary muscle rupture).

— Minimum 12 months aspirin + P2Y12 inhibitor.

— Extend beyond 12 months if high ischemic risk and low bleeding risk.

— Shorten to 1–6 months if high bleeding risk (PRECISE-DAPT, ARC-HBR).

— Bed rest 2–6 h post-radial/femoral; monitor access site.

— Telemetry, q4h vitals, daily ECG ×2.

— TTE within 24–48 h.

— Renal function check 24–48 h after contrast (CIN risk).

Primary PCI (preferred reperfusion):

Fibrinolysis (if PCI unavailable within 120 min):

CABG indications:

DAPT duration post-PCI for ACS:

Post-procedure orders (CCS):

CCS pearl: After PCI, document groin/radial exam, distal pulses, hematoma check at each reassessment. Retroperitoneal bleed presents as hypotension + back/flank pain + drop in Hgb — order non-contrast CT abdomen/pelvis stat.

Board pearl: No-reflow phenomenon after PCI: treat with intracoronary adenosine, nicardipine, or nitroprusside.

Special Populations — Elderly and Renal/Hepatic Impairment

— More likely atypical presentations (dyspnea, confusion, syncope).

— Higher mortality and higher bleeding risk; benefits of guideline therapy persist.

— Prasugrel: reduce to 5 mg daily if age ≥75 (or avoid unless prior MI/DM); standard dose may increase bleeding.

— Avoid IV beta-blockers acutely; start low oral doses.

— Use clopidogrel preferentially if frail or bleeding risk high.

— Consider radial access to minimize vascular complications.

— Watch for delirium post-cath — minimize benzodiazepines, opioids; reorient frequently.

— Troponin baseline often mildly elevated — focus on delta/rise-and-fall, not absolute value.

— Contrast nephropathy prevention: isotonic IV saline 1 mL/kg/h 6–12 h pre- and post-PCI; hold metformin; minimize contrast volume; use iso-osmolar contrast.

— Dose adjustments:

— Enoxaparin 1 mg/kg daily if CrCl <30.

— Eptifibatide/tirofiban: renal dose reductions.

— Avoid fondaparinux if CrCl <30.

— ACEi/ARB: monitor K and Cr at 1–2 weeks; acceptable rise ≤30%.

— Dialysis patients: still benefit from PCI; bleeding risk amplified.

— Ticagrelor contraindicated in severe hepatic dysfunction.

— Statins: atorvastatin and rosuvastatin generally safe in compensated disease; avoid in active liver disease/unexplained transaminase >3× ULN.

— Warfarin/DOAC dosing requires INR/Child-Pugh consideration.

— Transfuse RBC if Hgb <8 in ACS (MINT trial — liberal threshold 10 g/dL may benefit MI patients; evolving).

— Hold DAPT if platelets <50,000; cardiology/heme co-management.

Elderly (≥75 years):

Chronic kidney disease (CKD):

Hepatic impairment:

Anemia and thrombocytopenia:

Step 3 management: In an 82-year-old with NSTEMI, CrCl 35, on warfarin for AF — choose clopidogrel + reduced-dose anticoagulation, drop aspirin early (1–4 weeks) to dual therapy (OAC + P2Y12) per AUGUSTUS/PIONEER. Triple therapy >1 month rarely justified.

Special Populations — Pregnancy, Cocaine, and Younger Patients

— Most common cause: spontaneous coronary artery dissection (SCAD), especially peripartum.

— Diagnosis: ECG, troponin (unchanged in pregnancy), TTE; coronary angiography with abdominal shielding if needed.

— Management: conservative if stable (most SCAD heals); PCI reserved for ongoing ischemia/instability — high complication rate.

— Medications:

— Aspirin 81 mg: safe.

— Clopidogrel: limited data, use if needed.

— Beta-blockers: labetalol or metoprolol preferred; avoid atenolol (IUGR).

— Statins: traditionally avoided; emerging data may permit in high-risk; case-by-case.

— ACEi/ARB contraindicated — switch to hydralazine/nitrates.

— Heparin (UFH or LMWH): safe; warfarin and DOACs avoided.

— Mechanism: coronary vasospasm, thrombosis, accelerated atherosclerosis, demand ischemia.

— Treatment: benzodiazepines first (lorazepam 1–2 mg IV) to reduce sympathetic drive.

— Nitroglycerin and CCBs (verapamil, diltiazem) for vasospasm.

— Aspirin, heparin standard.

— Avoid pure beta-blockers acutely — unopposed alpha-stimulation may worsen vasoconstriction; labetalol acceptable in some guidelines after benzodiazepines.

— PCI if STEMI or refractory ischemia.

— Consider: cocaine, SCAD, vasculitis (Kawasaki sequelae, Takayasu), thrombophilia (antiphospholipid), familial hypercholesterolemia, anomalous coronary arteries.

— Family history of premature CAD critical.

— Always check lipid panel, Lp(a), and consider genetic counseling for FH.

— Workup: cardiac MRI to differentiate myocarditis, Takotsubo, infarct.

— Treat underlying cause (vasospasm, embolism, plaque erosion).

Pregnancy-associated MI:

Cocaine/methamphetamine-associated chest pain:

Young patients (<45):

MINOCA (MI with non-obstructive coronary arteries):

Board pearl: Peripartum woman with chest pain and troponin elevation — think SCAD first, not atherosclerotic plaque rupture. Conservative management is usually preferred.

Complications and Adverse Outcomes

— VT/VF: most common cause of early MI death; treat with defibrillation, amiodarone 150 mg IV bolus, lidocaine alternative.

— AV block:

— Inferior MI → AV nodal block (often transient, atropine-responsive); pacing rarely needed.

— Anterior MI → infranodal block (Mobitz II, complete heart block); transvenous pacing, often permanent.

— Sinus bradycardia: inferior MI, atropine 0.5 mg IV if symptomatic.

— AF post-MI: rate control, anticoagulate if persistent.

— Free wall rupture: sudden hypotension, JVD, PEA → tamponade; emergent surgery, often fatal.

— Ventricular septal rupture: new harsh holosystolic murmur, biventricular failure; echo with Doppler confirms; needs surgical repair or percutaneous closure.

— Papillary muscle rupture (usually posteromedial, RCA territory): acute severe MR, flash pulmonary edema, new murmur (may be soft); urgent valve surgery.

— LV aneurysm (weeks–months): persistent ST elevation, HF, thromboembolism.

— LV thrombus: large anterior MI, low EF; anticoagulate ×3–6 months (warfarin or DOAC).

— Cardiogenic shock: SBP <90, hypoperfusion, often anterior MI; treat with revascularization (CULPRIT-SHOCK: culprit-only PCI), inotropes (norepinephrine first-line over dopamine), mechanical support (IABP, Impella, VA-ECMO).

— RV infarct: hypotension + clear lungs + elevated JVP; fluid bolus, avoid nitrates/diuretics, dobutamine if persistent.

— Dressler syndrome (weeks post-MI): autoimmune pericarditis, fever, pleuritis; NSAIDs or aspirin + colchicine; avoid steroids and anticoagulation early (bleed/tamponade risk).

— Recurrent ischemia, stent thrombosis (early = mechanical, late = DAPT noncompliance).

— Heart failure, sudden cardiac death (ICD if EF ≤35% at 40 days).

Electrical complications (first 24–48 h):

Mechanical complications (days 3–7, classic timing):

Hemodynamic complications:

Late complications:

CCS pearl: New murmur + hemodynamic deterioration days 3–7 post-MI → order stat TTE, page cardiothoracic surgery, start inotropes and consider IABP while awaiting OR.

When to Escalate — ICU, Consults, and Inpatient Triage

— STEMI (all, minimum 24 h post-PCI).

— High-risk NSTEMI: hemodynamic instability, ongoing ischemia, malignant arrhythmia, LVEF <40%, mechanical complications.

— Cardiogenic shock, pulmonary edema (Killip III–IV).

— Post-cardiac arrest (initiate targeted temperature management 32–36°C ×24 h).

— Need for mechanical circulatory support, vasoactive infusions, or transvenous pacing.

— Uncomplicated NSTEMI post-PCI.

— Stable hemodynamics, no arrhythmia, controlled pain.

— Typical length of stay 2–4 days.

— Cardiology: every ACS — interventional for STEMI/high-risk NSTEMI.

— Cardiothoracic surgery: left main, complex multivessel, mechanical complications.

— Heart failure team: cardiogenic shock, LVAD/transplant candidacy.

— Electrophysiology: sustained VT/VF, complete heart block, ICD planning at 40 days.

— Nephrology: contrast nephropathy, dialysis coordination.

— Cardiac rehab referral: before discharge.

— STEMI: transfer if PCI achievable <120 min from first medical contact; otherwise fibrinolyse then transfer.

— Cardiogenic shock: emergent transfer to tertiary center with MCS capability regardless of distance.

— SBP <90 sustained, HR <40 or >130 with symptoms, SpO2 <90 on O2, altered mental status, recurrent chest pain with ECG changes.

CCU/ICU admission criteria:

Telemetry/step-down criteria:

Consult triggers (CCS: order early):

Transfer criteria (non-PCI center):

Rapid response/code triggers:

CCS pearl: Use the CCS "change location" command decisively — move from ED → cath lab → CCU as the case dictates. Lingering in the ED after STEMI diagnosis loses points.

Step 3 management: SCAI shock stage C or D (hypoperfusion + lactate >2) post-MI → escalate to mechanical support and tertiary transfer rather than escalating inotropes alone.

Key Differentials — Other Cardiovascular Causes of Chest Pain + Troponin

— Viral prodrome (Coxsackie, parvovirus, COVID), young patient, diffuse ST elevation/PR depression.

— Troponin elevated; ECG nonspecific.

— Cardiac MRI: late gadolinium enhancement in subepicardial/midwall (non-coronary distribution).

— Treat HF symptoms; avoid exercise ×3–6 months; some etiologies need immunosuppression.

— Postmenopausal woman, emotional/physical stressor.

— ECG mimics anterior MI (ST elevation, deep T inversions, QT prolongation).

— Apical ballooning on echo, normal coronaries on angiography.

— Supportive care; beta-blocker, ACEi; recovery in weeks.

— Avoid inotropes (LVOT obstruction in apical-sparing variant).

— Sharp pleuritic pain, relieved leaning forward, friction rub.

— Diffuse ST elevation with PR depression, no reciprocal changes.

— Troponin elevated if myocardial involvement.

— Treat with NSAIDs (ibuprofen 600 mg TID) + colchicine 0.5–0.6 mg BID ×3 months.

— Tearing pain, BP differential, mediastinal widening on CXR.

— May elevate troponin if coronary ostium involved (type A).

— CT aortogram diagnostic.

— Type A → emergent surgery; Type B → IV beta-blocker (esmolol) first, then nitroprusside; target HR <60, SBP 100–120.

— Do not give antiplatelets/anticoagulants until dissection excluded.

— Rest pain, transient ST elevation, often nocturnal.

— Triggered by cold, hyperventilation, stimulants.

— Diagnose with ergonovine/acetylcholine provocation if equivocal.

— Treat with CCBs (amlodipine, diltiazem) + long-acting nitrates; avoid non-selective beta-blockers.

— Sepsis, severe anemia, tachyarrhythmia, hypertensive crisis, hypoxia.

— Treat the precipitant; no role for emergent PCI.

Myocarditis:

Takotsubo (stress) cardiomyopathy:

Pericarditis/myopericarditis:

Aortic dissection:

Coronary vasospasm (Prinzmetal):

Demand ischemia/Type 2 MI:

Key distinction: Diffuse concave-up ST elevation with PR depression = pericarditis; focal ST elevation with reciprocal depression = STEMI. PR depression in aVR and elevation in II are pericarditis hallmarks.

Key Differentials — Non-Cardiac Causes of Chest Pain

— Pleuritic chest pain, dyspnea, tachycardia, hypoxia, unilateral leg swelling.

— ECG: sinus tachycardia (most common), S1Q3T3, RV strain pattern.

— Troponin and BNP may elevate (RV strain) — mimics ACS.

— D-dimer if low/intermediate Wells; CTPA if positive or high pretest probability.

— Treat: anticoagulation (heparin → DOAC); thrombolysis if massive (hemodynamic instability).

— Sudden pleuritic pain, dyspnea, tracheal deviation, absent breath sounds, hypotension.

— Clinical diagnosis — needle decompression 2nd ICS midclavicular or 5th ICS anterior axillary, then chest tube.

— GERD: burning retrosternal pain, postprandial, relieved by antacids.

— Esophageal spasm: mimics angina, may respond to nitrates (diagnostic pitfall).

— Boerhaave syndrome: severe pain after vomiting, subcutaneous emphysema, mediastinitis; CT chest, surgical/endoscopic repair.

— Costochondritis: reproducible tenderness, NSAIDs.

— Tietze syndrome: swelling of costochondral junction.

— Diagnosis of exclusion after cardiac rule-out.

— Dermatomal burning pain preceding vesicular rash.

— Antivirals within 72 h (valacyclovir 1 g TID ×7 days).

— Diagnosis of exclusion; co-existing CAD common.

— Don't anchor — still complete cardiac workup.

— Fever, productive cough, focal exam findings, infiltrate on CXR.

— Fever, leukocytosis, sternal instability/crepitus, widened mediastinum.

— Broad-spectrum antibiotics, surgical debridement.

Pulmonary embolism:

Tension pneumothorax:

Esophageal causes:

Musculoskeletal:

Herpes zoster:

Anxiety/panic disorder:

Pneumonia/pleurisy:

Mediastinitis (post-CABG, Boerhaave):

Step 3 management: A patient with chest pain, low HEART score, negative troponins ×2, but persistent symptoms → do not discharge with "noncardiac chest pain" label alone. Address GERD trial, MSK eval, anxiety screen, and outpatient stress test or CCTA within 72 h with documented follow-up.

Secondary Prevention and Discharge Medications

— A: Aspirin 81 mg daily indefinitely + P2Y12 inhibitor ×12 months (DAPT).

— A: ACEi/ARB (lisinopril, losartan) — especially if LVEF <40%, HTN, DM, or anterior MI.

— B: Beta-blocker (metoprolol succinate, carvedilol, bisoprolol) — continue ≥1 year all post-MI; indefinitely if EF reduced.

— C: Cholesterol — high-intensity statin (atorvastatin 80 or rosuvastatin 20–40); LDL goal <70 mg/dL, consider <55 if very high risk. Add ezetimibe 10 mg if not at goal; PCSK9 inhibitor (evolocumab, alirocumab) if still uncontrolled.

— C: Cardiac rehab referral — Class I indication, reduces mortality 20–30%.

— D: Diet (Mediterranean), Diabetes control (HbA1c <7%, prefer SGLT2i/GLP-1 RA for cardiovascular benefit), Depression screen (PHQ-9).

— E: Exercise (≥150 min moderate/week), Education on symptom recognition, sublingual nitro use, smoking cessation.

— Mineralocorticoid antagonist (eplerenone 25 mg → 50 mg, spironolactone) if EF ≤40% + symptomatic HF or DM, on ACEi/BB.

— SGLT2 inhibitor (empagliflozin, dapagliflozin) if HFrEF, DM, or CKD.

— Icosapent ethyl 2 g BID if persistent triglycerides 150–499 on statin (REDUCE-IT).

— Colchicine 0.5 mg daily (LoDoCo2): selective use in stable CAD for anti-inflammatory benefit.

— Smoking cessation: varenicline or bupropion + nicotine replacement; counseling at every visit.

— Alcohol: ≤1 drink/day women, ≤2 men.

— Weight loss to BMI <25; BP <130/80.

— Influenza vaccine annually; pneumococcal and COVID per CDC.

— Sexual activity: safe ~1 week post-uncomplicated MI; nitrates contraindicate PDE-5 inhibitors.

The "ABCDE" post-MI discharge bundle:

Specialty additions:

Lifestyle:

Driving restrictions: 1 week post-uncomplicated NSTEMI/PCI; 4 weeks post-STEMI or CABG (varies by state).

Board pearl: ICD evaluation at 40 days post-MI if LVEF ≤35% with NYHA II–III on optimal medical therapy. Earlier ICD does not improve mortality (DINAMIT, IRIS).

Follow-Up, Monitoring, and Cardiac Rehab

— 7–14 days: PCP or cardiology follow-up — review symptoms, medication adherence, side effects, BP, HR, vascular access site.

— 4–6 weeks: Cardiology — titrate beta-blocker, ACEi, statin; repeat lipid panel (target LDL <70).

— 3 months: Repeat TTE if initial LVEF <40% to reassess for ICD candidacy at 40-day mark or post-revascularization recovery.

— 6 and 12 months: Symptom assessment, DAPT continuation decision, lipid and HbA1c check.

— Annual thereafter: comprehensive cardiac risk reassessment.

— Begin within 2–4 weeks of discharge.

— 36 supervised sessions over 12 weeks (Medicare standard).

— Includes monitored exercise, risk factor education, dietary counseling, psychosocial support.

— Class I recommendation; documented mortality benefit. Address insurance/transportation barriers proactively.

— Lipid panel at 4–12 weeks post-statin start, then annually.

— LFTs at baseline; recheck only if symptoms (myalgia, jaundice).

— CK if myalgia on statin; consider rosuvastatin or alternate-day dosing if intolerant.

— BMP at 1–2 weeks after ACEi/MRA initiation: K and Cr.

— HbA1c every 3 months until at goal, then every 6 months.

— BP at every visit, goal <130/80.

— Depression screen (PHQ-9) at 2–3 months — post-MI depression doubles mortality.

— Recognize recurrent symptoms; call 911 not drive in.

— Sublingual nitro technique: one tab q5 min ×3, call EMS if not relieved after first dose with ongoing symptoms.

— Medication adherence — DAPT discontinuation is the leading preventable cause of stent thrombosis.

— Return-to-work timeline: sedentary 1–2 weeks, moderate 2–4 weeks, heavy labor 4–6 weeks; individualized post-cardiac rehab stress test.

Post-discharge cadence:

Cardiac rehab (Phase II):

Monitoring parameters:

Counseling priorities:

CCS pearl: Before "end case," always order: cardiac rehab referral, lipid panel in 4 weeks, PCP follow-up in 1–2 weeks, cardiology follow-up in 4–6 weeks, smoking cessation counseling, and patient education on red-flag symptoms.

Ethical, Legal, and Patient Safety Considerations

— STEMI patients may have impaired decisional capacity from pain, hypoxia, or sedation.

— Use emergency exception to consent (implied consent) for life-saving PCI/fibrinolysis if patient unable to consent and no surrogate immediately available.

— Document the emergency, attempted surrogate contact, and clinical necessity.

— Capacitated patient may refuse PCI even with STEMI; document capacity assessment (understanding, appreciation, reasoning, communication), risks explained, and offer alternatives.

— Jehovah's Witness: discuss blood product alternatives (cell salvage, tranexamic acid, erythropoietin); honor advance directive but ensure it's current and specific.

— ED → cath lab → CCU → floor → discharge: each handoff is a medication-error opportunity.

— Medication reconciliation at each transition is a Joint Commission National Patient Safety Goal.

— Use structured handoff (SBAR, I-PASS).

— Discharge summary to PCP within 48 h; pending labs/tests flagged.

— Counsel patient and family explicitly; provide wallet card with stent type/date.

— Coordinate with surgeons/dentists — defer elective surgery 6 months post-DES if possible; for urgent surgery, continue aspirin and consider bridging.

— Commercial drivers (CDL): 3 months off after MI per FMCSA; documentation required.

— Pilots, public safety officers: institution-specific clearance.

— Women, Black patients, and those without insurance are less likely to receive timely PCI, guideline-directed therapy, and cardiac rehab referral. Apply protocols uniformly.

— Explicit decision-support tools (HEART, GRACE) reduce bias.

— Suspected cocaine-induced MI does not require law-enforcement reporting in most states (PHI protections).

— Impaired driving causing harm may trigger DMV reporting per state law.

— Contrast nephropathy, bleeding, vascular complications, and HAI (CLABSI, CAUTI) — bundle prevention.

— Use the CHA2DS2-VASc and HAS-BLED for AF patients post-MI to balance antithrombotic intensity.

Informed consent for emergent procedures:

Refusal of care:

Transitions of care — high-risk moments:

Premature DAPT discontinuation:

Driving and occupational restrictions:

Disparities and bias:

Mandatory reporting:

Patient safety:

Step 3 pearl: Always document shared decision-making for DAPT duration, ICD placement, and revascularization choice — these are recurrent legal and exam scenarios.

High-Yield Associations and Rapid-Fire Facts

— Anterior (V1–V4): LAD.

— Lateral (I, aVL, V5–V6): LCx or diagonal.

— Inferior (II, III, aVF): RCA (85%) or LCx (15%).

— Posterior (V1–V3 ST depression, V7–V9 elevation): RCA or LCx.

— RV (V4R): proximal RCA.

— Inferior MI: ST depression in I, aVL.

— Anterior MI: ST depression in II, III, aVF (less consistent).

— 0–24 h: arrhythmia (VF), cardiogenic shock.

— 1–3 days: pericarditis (early, peri-infarct).

— 3–7 days: mechanical (free wall, septal, papillary muscle rupture).

— Weeks–months: Dressler syndrome, LV aneurysm, LV thrombus, HF.

— Ticagrelor causes dyspnea (~15%) and bradyarrhythmias; reversible, often no intervention needed.

— Clopidogrel: CYP2C19 poor metabolizers have reduced efficacy.

— Statins: rhabdomyolysis risk ↑ with gemfibrozil, macrolides, azoles; use fenofibrate instead.

— Nitrate tolerance: need 10–12 h nitrate-free interval daily.

— hs-cTn detectable within 1 h, peaks 12–24 h, normalizes 7–10 days.

— CK-MB (less used now) peaks 24 h, normalizes 48–72 h — useful for reinfarction detection within 1 week.

— DTB ≤90 min (PCI), ≤120 min if transfer.

— DTN ≤30 min (fibrinolysis).

ECG localization:

Reciprocal changes:

Timing of post-MI complications:

Drug-specific pearls:

Troponin timing:

Door-to-balloon and door-to-needle:

Anticoagulation after MI for LV thrombus: Warfarin INR 2–3 ×3–6 months; DOACs acceptable (off-label but increasing evidence).

Aspirin allergy: Desensitization in cath lab if true allergy; otherwise clopidogrel monotherapy not equivalent.

GLP-1 RA and SGLT2i: cardiovascular mortality benefit independent of glycemic control.

Board pearl: New RBBB in anterior MI = proximal LAD occlusion = high mortality; consider it a STEMI equivalent.

Key distinction: Stunned myocardium (reversible, post-ischemic dysfunction) vs hibernating myocardium (chronic ischemia, viable, recovers with revascularization) — both have reduced wall motion but preserved viability on PET/MRI.

Board Question Stem Patterns

— 62 M, chest pain, ECG shows ST elevation II/III/aVF. BP 82/50, lungs clear, JVD elevated. Next step?

— Answer: Right-sided ECG (V4R); if RV infarct → IV normal saline bolus, avoid nitrates and diuretics, then PCI.

— Patient with NSTEMI and prior stroke 2 years ago. Which P2Y12 inhibitor?

— Answer: Ticagrelor (not prasugrel — absolute contraindication with prior CVA/TIA).

— Patient with intermittent chest pain, now pain-free; ECG shows deep symmetric T inversions V2–V3, troponin negative. Next step?

— Answer: Cardiac catheterization — critical proximal LAD stenosis; do not stress test.

— Post-MI day 5, sudden hypotension, new harsh holosystolic murmur, biventricular failure. Diagnosis?

— Answer: Ventricular septal rupture; emergent TTE with Doppler, cardiothoracic surgery consult, IABP.

— 28 M, chest pain, agitated, BP 180/100, ECG ST depression. First-line therapy?

— Answer: Lorazepam + sublingual nitroglycerin + aspirin; avoid pure beta-blockers acutely.

— Anterior STEMI 2 weeks ago, LVEF 25% on optimal medical therapy. ICD now?

— Answer: Wait until 40 days post-MI to reassess EF; ICD if EF still ≤35%.

— STEMI patient discharged on aspirin, clopidogrel, atorvastatin, lisinopril. What's missing?

— Answer: Beta-blocker (e.g., metoprolol succinate).

— Septic patient with troponin elevation, no chest pain, ECG with sinus tachycardia. Next step?

— Answer: Treat sepsis; no role for emergent cath; reassess after stabilization.

— Week 4 post-MI, fever, pleuritic chest pain, friction rub. Diagnosis and treatment?

— Answer: Dressler syndrome; NSAIDs or aspirin + colchicine; avoid steroids/anticoagulants early.

— 34 F, 3 weeks postpartum, chest pain, troponin elevated, angiogram shows long tapering coronary lesion. Management?

— Answer: Conservative medical therapy; PCI only if ongoing ischemia/instability.

Pattern 1 — Inferior MI with hypotension:

Pattern 2 — Prasugrel contraindication:

Pattern 3 — Wellens / De Winter T waves:

Pattern 4 — Mechanical complication day 5:

Pattern 5 — Cocaine chest pain:

Pattern 6 — Post-MI ICD timing:

Pattern 7 — Discharge medications missing:

Pattern 8 — Type 2 MI:

Pattern 9 — Dressler vs early pericarditis:

Pattern 10 — SCAD:

One-Line Recap

Acute coronary syndrome with troponin elevation is a time-critical diagnosis where the first 10 minutes (ECG, aspirin, dual access, risk stratification) determine whether the patient gets emergent reperfusion for STEMI or risk-stratified invasive vs ischemia-guided management for NSTE-ACS, followed by lifelong guideline-directed secondary prevention.

Diagnostic core: ECG within 10 min + serial hs-troponin with delta + risk score (HEART/TIMI/GRACE) determines disposition; STEMI = cath lab now (DTB ≤90 min), high-risk NSTEMI = cath within 2–24 h, low-risk = observation with stress/CCTA.

Acute therapy bundle: Aspirin 325 mg chewed + P2Y12 (ticagrelor preferred, not prasugrel if prior stroke) + anticoagulation (heparin or enoxaparin) + high-intensity statin + beta-blocker within 24 h + ACEi if EF <40%/anterior MI/DM/HTN; oxygen only if SpO2 <90%; morphine only if refractory.

Watch for traps: RV infarct (fluids, no nitrates), mechanical complications days 3–7 (new murmur + crash), cocaine chest pain (benzo first), SCAD in peripartum women, Wellens/De Winter (LAD equivalents), prasugrel contraindication in prior CVA, ICD evaluation deferred to 40 days post-MI.

Discharge essentials (ABCDE): Aspirin + P2Y12 ×12 mo, ACEi/ARB, Beta-blocker, Cholesterol (atorvastatin 80), Cardiac rehab, Diet/Diabetes/Depression screen, Exercise/Education; follow-up at 1–2 weeks PCP, 4–6 weeks cardiology, repeat TTE at 3 months if EF reduced, lifelong risk-factor optimization with documented shared decision-making at every transition of care.